Review Highlights Growing Dangers of Falsified Biotechnology Drugs

Biotechnology drugs, also known as biologics, are complex medicines derived from living organisms, essential for treating severe conditions like cancer, autoimmune disorders, and diabetes. Their intricate manufacturing processes make them particularly vulnerable to falsification, posing significant public health risks. This comprehensive review addresses the current landscape of falsified biotechnology drugs and their potential for future catastrophic impact on patient safety and global healthcare systems.

The review revealed that falsified biotechnology drugs represent a pervasive and escalating global threat, frequently containing no active pharmaceutical ingredient (API), incorrect dosages (e.g., as low as 20% of the stated dose), or harmful contaminants. It underscored the difficulty of detection, noting that sophisticated counterfeits often mimic authentic packaging with up to 95% visual accuracy. The paper identified a significant increase in reported incidents, documenting a 3-fold rise in the last decade, with a disproportionate impact on developing nations. The most critical finding was that falsified biologics frequently lead to treatment failure and severe adverse events, with over 15% of reported cases resulting in hospitalization or patient mortality, directly threatening patient lives. The authors also highlighted the substantial economic burden, estimated at billions of dollars annually in lost revenue and increased healthcare costs.